PF-06835375 / Pfizer 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PF-06835375 / Pfizer
2021-002897-19: A Phase 2 Open-Label Safety and Efficacy Study of PF-06835375 in adult participants with Immune thrombocytopenia, a disorder in which there is a reduced amount of platelets in the blood stream which are important for blood to clot normally A PF-06835375 II. fázisú, nyílt biztonságossági és hatásossági vizsgálata immunthrombocytopeniás felnőttekben

Not yet recruiting
2
40
Europe
PF-06835375, PF-06835375, Solution for injection
Pfizer Inc., Pfizer Inc.
Primary immune thrombocytopenia, Immune thrombocytopenia is a disorder characterized by a blood abnormality called thrombocytopenia, which is a shortage of blood cells called platelets that are needed for normal blood clotting., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT05070845: Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

Recruiting
2
61
Europe, Canada, US, RoW
PF-06835375
Pfizer
Primary Immune Thrombocytopenia
10/26
10/26

Download Options